Abstract Aims Previous DREAM studies demonstrated the safety and efficacy of the CE marked MD‐Logic closed‐loop system (DreaMed GlucoSitter) in different settings for overnight glycaemic control. The present study aimed to evaluate the system for day and night use for 60 hours during the weekend at home compared to sensor‐augmented pump (SAP) therapy in participants with type 1 diabetes. Methods This was a prospective, multicentre, crossover, controlled study (clinicaltrials.gov NCT01238406).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile